COMPARE THE EVIDENCE

Tirzepatide

Findings, possible implications, and reported experiences.

About Tirzepatide

PeptideMetabolism

Primary research area: Metabolism · diabetes & obesity
Regulatory status: Prescription medicine
Evidence level: Large human evidence
Primary mechanism: GIP and GLP-1 receptor agonist

Reference profile available · Coverage varies by section

Also known as LY3298176 · Mounjaro · Zepbound

Tirzepatide activates GIP and GLP-1 receptors. It affects glucose regulation and food intake. Mounjaro and Zepbound contain the same active compound with different labeled uses. [1][2]

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Human · Reading scope not recorded

How does tirzepatide compare with semaglutide for weight loss?

72 weeks; maximum tolerated tirzepatide 10/15 mg versus semaglutide 1.7/2.4 mg; adults without diabetes.

Average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks.

Limits: Adults with obesity without diabetes; open-label trial. It does not compare all doses or establish an overall winner for every health outcome.

Open primary source · Read interpretation separately

Human · Abstract reviewed

How much of the weight lost was lean mass?

SURMOUNT-1 DXA substudy: 124 tirzepatide and 36 placebo participants; 72 weeks.

At 72 weeks, fat mass fell 33.9% and lean mass 10.9% with pooled tirzepatide doses, versus 8.2% and 2.6% with placebo. About a quarter of the weight lost was lean mass in both groups.

Limits & adverse findings: DXA lean mass is not a direct measure of contractile muscle or strength. This was a 160-person substudy, not the full randomized population. Both fat and lean mass declined. These results do not establish muscle preservation.

Open primary source · Read interpretation separately

Explore outcomes for this compound

Uses & research: Mounjaro is used for type 2 diabetes. Zepbound is used for chronic weight management and obstructive sleep apnea in specified populations. [1][2]
Known half-life: About 5 days in the Mounjaro label; about 5–6 days in the Zepbound label for people with overweight or obesity, including obstructive sleep apnea populations. [1][2]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: Benefits and eligibility depend on the indication and population. The labels include gastrointestinal effects, pancreatitis warnings and a boxed warning about thyroid C-cell tumors observed in rats. [1][2]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Benefits and eligibility depend on the indication and population. The labels include gastrointestinal effects, pancreatitis warnings and a boxed warning about thyroid C-cell tumors observed in rats.

Mounjaro prescribing information Zepbound prescribing information

Human study: Both fat and lean mass declined. These results do not establish muscle preservation. Source

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: Tirzepatide · tirzepatide

Searchable names: LY3298176, Mounjaro, Zepbound

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

1. Mounjaro prescribing information Drug label · indications, warnings and clinical pharmacology
2. Zepbound prescribing information Drug label · indications, warnings and clinical pharmacology

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…